The Janus Kinase inhibitor tofacitinib impacts human dendritic cell differentiation and favours M1 macrophage development

Several cytokines signalling via Janus Kinase (JAK) proteins have been implicated in the pathogenesis of immune‐mediated inflammatory diseases, including psoriasis and rheumatoid arthritis (RA). Tofacitinib, a small JAK inhibitor, is approved for the treatment of RA and has demonstrated good efficac...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Experimental dermatology 2020-01, Vol.29 (1), p.71-78
Hauptverfasser:	Stalder, Romaine, Zhang, Bin, Jean Wrobel, Ludovic, Boehncke, Wolf‐Henning, Brembilla, Nicolo Costantino
Format:	Artikel
Sprache:	eng
Schlagworte:	CD80 antigen Cell differentiation Clinical trials Cytokines Dendritic cells Enzyme inhibitors IL‐23 Inflammatory diseases Janus kinase Janus kinase inhibitor Lipopolysaccharides Macrophages Monocytes Nitric-oxide synthase Phenotypes Psoriasis Rheumatoid arthritis tofacitinib Transcription γ-Interferon
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!